T2 Biosystems to Present Data on T2Candida at asm2015

LEXINGTON, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that new data on the company's T2Candida® Panel will be presented at asm2015, the 115th General Meeting of the American Society for Microbiology, being held May 30-June 2, 2015, at the New Orleans Ernest N. Morial Convention Center. Two posters will highlight the impact of T2Candida in the diagnosis of candidemia in patients using 2ml of blood, as well as the economic and mortality impact of T2Candida for rapid candida diagnosis among high-risk patients, as reported in a recent publication in Future Microbiology.

The schedule for asm2015 presentations is as follows:

Title: The Economic and Mortality Impact of Rapid Candida Species Identification by T2Candida Among High-Risk Patients
Date & Time: Monday, June 1, 2015, 12:30-1:45 p.m.
Session: Poster (#1470)
Session Title: Identification/Detection: Multiplex II (Division C)
Location: Exhibit Hall E
Presenters: Mike Pfaller, M.D., T2 Biosystems
Title: T2Candida Provides Rapid and Accurate Species Identification in Cases of Candidemia using 2ml of blood
Date & Time: Tuesday, June 2, 2015, 10:45 a.m.-12:00 p.m.
Session: Poster (#2017)
Session Title: Mycobacteriology and Mycology (Division C)
Location: Exhibit Hall E
Presenters: Camille Hamula, Ph.D., Icahn School of Medicine, Mount Sinai Hospital

T2 Biosystems will also sponsor a symposium, "Implementing T2Candida for high-risk patients: the impact on hospital mortality, economics and resistance," on Monday, June 1, 2015, at 6:30 p.m. at the New Orleans Downtown Marriott – Meeting Room Blaine Kern D-F. Speakers include:

  • Angela M. Caliendo, M.D., Ph.D., professor and executive vice chair, Department of Medicine, Alpert Medical School of Brown University
  • Kevin W. Garey, PharmD, M.S., FASHP, chair, Department of Clinical Sciences & Administration, professor of pharmacy practice, University of Houston
  • Pinar Bilir, B.S., M.S., director, US HEOR and Real World Evidence Solutions, IMS Health, Danbury, CT
  • Luis Ostrosky-Zeichner, M.D., professor of medicine and epidemiology, director, Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Medical School

Additionally, Rahul Dhanda, vice president, marketing at T2 Biosystems will participate in the Diagnostic Marketing Association (DxMA) Seminar at asm2015. The details of the panel presentation are as follows:

Title: The Path to Adoption of Disruptive Technologies: Focus on New Solutions for Rapid ID/AST
Date & Time: Saturday, May 30, 2015, 3:30-5:00 p.m.
Session: DxMA Seminar
Location: Ernest N. Morial Convention Center - Meeting Room 265

About The T2Candida Panel

The T2Candida Panel is the first sepsis pathogen diagnostic that provides species-specific results in three to five hours without the need for blood culture, which can take up to six days to provide a result. The rapid detection of Candida enables physicians to provide targeted treatment quickly, and research has shown this can reduce a positive sepsis patient's length of stay in the hospital by almost nine days at a cost savings of approximately $26,887. A rapid negative result can prevent unnecessary administration of antimicrobials, further reducing costs. In addition, a rapid negative result can prevent or reduce antimicrobial resistance, which the Centers for Disease Control and Prevention has designated a serious threat.

About Candida

Candidemia is a systemic fungal infection that occurs when Candida organisms in the blood spread to organs and tissues throughout the body. Candidemia is the fourth leading hospital-acquired bloodstream infection and the most lethal form of common bloodstream infection that cause sepsis, according to the Center for Disease Control (CDC), with an approximate 40 percent mortality rate. In the absence of a rapid, accurate diagnostic, appropriate therapeutic intervention for candidemia is often delayed, resulting in a mortality rate that is three to four times higher than when early, targeted therapy is initiated. According to a study published in Antimicrobial Agents and Chemotherapy, the mortality rate can be reduced to 11 percent with the initiation of targeted therapy within 12 hours of presentation of symptoms. On average, candidemic patients require 40 days of hospitalization and have a hospital cost of $130,000.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2015, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

CONTACT: Media Contact: Katie Engleman, Pure Communications katie@purecommunicationsinc.com 910-509-3977 Investor Contact: Matt Clawson, Pure Communications matt@purecommunicationsinc.com 949-370-8500Source:T2 Biosystems, Inc.